Lamotrigine Safety in Parkinson's Disease
Lamotrigine (Lamictal) is not recommended for use in patients with Parkinson's disease, as clinical trials have failed to demonstrate antiparkinsonian efficacy and there are concerning associations between antiepileptic drugs and incident Parkinson's disease.
Evidence Against Use in Parkinson's Disease
The clinical evidence consistently shows lamotrigine lacks therapeutic benefit in PD:
Two double-blind, placebo-controlled trials specifically tested lamotrigine in PD patients and found no significant improvement in motor symptoms 1, 2. The larger crossover study was particularly telling: 9 of 12 patients discontinued lamotrigine due to worsening dyskinesia (n=2), hallucinations (n=3), and deterioration of parkinsonian symptoms (n=4) 2.
Animal models similarly failed to show antiparkinsonian activity, with lamotrigine demonstrating no benefit in reserpinized rats or 6-hydroxydopamine lesioned models when given alone or combined with dopamine agonists 3.
Epidemiological Concerns
Recent large-scale observational studies raise additional safety concerns:
A UK Biobank nested case-control study (n=1,433 PD cases, 8,598 controls) found antiepileptic drug prescriptions were associated with 1.80 times higher odds of incident PD (95% CI: 1.35-2.40), with a dose-response relationship showing greater risk with more prescriptions 4.
A German primary care database study (n=24,950 matched pairs) confirmed this association, finding any AED prescription was associated with 1.43 times higher odds of subsequent PD diagnosis (95% CI: 1.33-1.53), even after adjusting for epilepsy, restless legs syndrome, and neuropathy 5.
While these studies cannot establish causality and may reflect confounding by indication (epilepsy itself is associated with PD risk), they provide no reassurance about lamotrigine safety in this population.
FDA Labeling Considerations
The FDA label for lamotrigine does not specifically address use in Parkinson's disease 6. However, it notes that lamotrigine clearance may be affected in elderly patients (common PD demographic), with mean half-life of 31.2 hours in patients aged 65-76 years 6.
Clinical Context
The theoretical rationale for lamotrigine in PD—that it inhibits presynaptic glutamate release and might counteract excessive glutamatergic transmission in the basal ganglia—has not translated into clinical benefit 1, 7. The one positive finding was limited to a small pilot study showing investigator-assessed improvement (6/10 vs 2/10, p<0.05) without objective motor improvements 1.
Practical Recommendation
If a patient with Parkinson's disease requires seizure management:
- Prioritize alternative antiepileptic drugs with established safety profiles in PD
- Avoid lamotrigine unless other options are contraindicated or have failed
- If lamotrigine must be used, monitor closely for worsening motor symptoms, hallucinations, and dyskinesia
- Consider neurology consultation for medication selection in this complex scenario
The convergence of negative efficacy trials, concerning epidemiological associations, and high discontinuation rates due to adverse effects in PD patients makes lamotrigine a poor choice for this population.